Sanofi has announced the acquisition of Principia Biopharma, a late-stage biopharmaceutical company involved in developing therapies in the field of autoimmune and allergic diseases.
As per the agreement, Sanofi will acquire all the outstanding shares by paying $100 in cash; the value of the deal is 3.68 billion.
The acquisition accorded Sanofi three BTK inhibitors in the pipeline, which help in treating autoimmune diseases. The drugs act by blocking or disrupting the signaling processes, which can help in stopping inflammation and tissue destruction, related to autoimmune diseases. The drug candidates are developed based on Principia BioPharma’s Tailored Covalency platform.
Rilzabrutinib:
An oral, reversible covalent BTK inhibitor, is in Phase 3 clinical trial to evaluate the efficacy in patients suffering from moderate to severe pemphigus.
Further, the drug is in Phase 1/2 clinical trial for treating patients with immune thrombocytopenia (ITP). The company is planning to initiate a Phase 3 trial to confirm its efficacy.
The company is also planning to initiate a Phase 2 clinical trial in IgG4-Related diseases.
PRN2246/SAR442168:
An oral covalent BTK inhibitor licensed to Sanofi since 2017. Sanofi is planning to evaluate the efficacy in relapsing and progressing MS patients in four clinical trials.
PRN473:
A topical, reversible covalent BTK inhibitor is currently in the Phase 1 stage of development for immune-mediated diseases.
If the information is useful and would like to support us, please help by clicking donate button on the header and donate. Your contribution makes a big difference to us
For pipeline, market overview, SLRs, and market access reports (syndicate and customised) please write to sales@firstviewinsight.com
For all syndicate reports: Click here
Comentarios